Key result
Concomitant tricuspid repair during minimally invasive mitral surgery linked to ~99% higher pacemaker risk.
Why the study?
Randomized evidence suggests a high risk of pacemaker implantation for patients undergoing mitral valve surgery with concomitant tricuspid valve repair, but the impact on outcomes in minimally invasive surgery is unclear.
Does concomitant tricuspid valve repair increase the risk of postoperative pacemaker implantation in patients undergoing minimally invasive mitral valve surgery?
Cohort (n=7,513)
Yes
Does concomitant tricuspid valve repair increase the risk of postoperative pacemaker implantation in patients undergoing minimally invasive mitral valve surgery?
Concomitant tricuspid valve repair during minimally invasive mitral valve surgery independently increases the risk of postoperative permanent pacemaker implantation, bleeding, and acute kidney injury.
Answers are grounded in this paper and cite their sources.
May warrant caution with concomitant tricuspid repair in minimally invasive mitral surgery; extends randomized evidence but leaves practice change open pending trials.
Objective Randomized evidence suggests a high risk of pacemaker implantation for patients undergoing mitral valve (MV) surgery with concomitant tricuspid valve repair (cTVR). We investigated the impact of cTVR on outcomes in the Mini-Mitral International Registry. Methods From 2015 to 2021, 7513 patients underwent minimally invasive MV with or without cTVR in 17 international centers (MV: n = 5609, cTVR: n = 1113). Propensity matching generated 1110 well-balanced pairs. Multivariable analysis was applied. Results Patients with cTVR were older and had more comorbidities. Propensity matching eliminated most differences except for more TR in patients who underwent cTVR (77.2% vs 22.1% MV, P < .001). Mean matched age was 71 years, and 45% were male. European System for Cardiac Operative Risk Evaluation II was still 2.68% (interquartile range [IQR], 0.80-2.63) vs 1.9% (IQR, 1.12-3.9) in matched MV ( P < .001). MV replacement (30%) and atrial fibrillation surgery (32%) were similar in both groups. Cardiopulmonary bypass (161 minutes [IQR, 133-203] vs MV: 130 minutes [IQR, 103-166]; P < .001) and crossclamp times (93 minutes [IQR, 66-123] vs MV: 83 minutes [IQR, 64-107]; P < .001) were longer with cTVR. Although in-hospital mortality was similar (cTVR: 3.3% vs MV: 2.2%; P = .5), postoperative pacemaker implantations (9% vs MV: 5.8%; P = .02), low cardiac output syndrome (7.7% vs MV: 4.4%; P = .02), and acute kidney injury (13.8% vs MV: 10%; P = .01) were more frequent with cTVR. cTVR eliminated relevant TR in most patients (greater-than-moderate TR: 6.8%). Multivariable analysis identified MV replacement, atrial fibrillation, and cTVR as risk factors of postoperative pacemaker implantation. Conclusions cTVR in minimally invasive MV surgery is an independent risk factor for pacemaker implantation in this international registry. It is also associated with more bleeding, low output syndrome, and acute kidney injury. It remains unclear whether technical or patient factors (or both) explain these differences.
No takes yet. Share an insight, caveat, or question.
Faerber et al. (2023) conducted a cohort in Mitral valve disease requiring surgery (n=7,513). Concomitant tricuspid valve repair (cTVR) vs. Mitral valve surgery alone was evaluated on Postoperative permanent pacemaker implantation (OR 1.993, 95% CI 1.128-3.523, p=0.02). Concomitant tricuspid valve repair during minimally invasive mitral valve surgery increased the risk of postoperative pacemaker implantation compared to mitral surgery alone (9% vs 5.8%; OR 1.993).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: